Inhibition of <scp>CBP</scp> /β‐catenin signaling ameliorated fibrosis in cholestatic liver disease-Reference-Cited by-同舟云学术

Inhibition of CBP /β‐catenin signaling ameliorated fibrosis in cholestatic liver disease

Published:2022-07-20 Issue:10 Volume:6 Page:2732-2747
ISSN:2471-254X
Container-title:Hepatology Communications
language:en
Short-container-title:Hepatology Communications

Author:

Kimura Masamichi¹,Nishikawa Koji¹,Osawa Yosuke²,Imamura Jun¹,Yamaji Kenzaburo³,Harada Kenichi⁴,Yatsuhashi Hiroshi⁵,Murata Kazumoto⁶,Miura Kouichi⁷,Tanaka Atsushi⁸,Kanto Tatsuya⁹,Kohara Michinori³,Kamisawa Terumi¹⁰,Kimura Kiminori¹^ORCID

Affiliation:

1. Department of Hepatology Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital Tokyo Japan

2. Department of Gastroenterology International University of Health and Welfare Hospital Nasushiobara Japan

3. Department of Microbiology and Cell Biology Tokyo Metropolitan Institute of Medical Science Tokyo Japan

4. Department of Human Pathology Kanazawa University Graduate School of Medicine Kanazawa Japan

5. Clinical Research Center National Hospital Organization Nagasaki Medical Center Omura Japan

6. Division of Virology Department of Infection and Immunity Jichi Medical University School of Medicine Tochigi Japan

7. Division of Gastroenterology Department of Medicine Jichi Medical University Tochigi Japan

8. Department of Medicine Teikyo University School of Medicine Tokyo Japan

9. The Research Center for Hepatitis and Immunology National Center for Global Health and Medicine Ichikawa Japan

10. Department of Gastroenterology Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital Tokyo Japan

Funder

Japan Agency for Medical Research and Development

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hep4.2043

Reference34 articles.

1. Primary biliary cholangitis

2. Ursodiol for the Long-Term Treatment of Primary Biliary Cirrhosis

3. Association of bezafibrate with transplant-free survival in patients with primary biliary cholangitis

4. A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis

5. Novel therapeutic targets for cholestatic and fatty liver disease

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Induction of the Lipid Droplet Formation Genes in Steatohepatitis Mice by Embryo/Postnatal Nutrient Environment Is Associated with Histone Acetylation around the Genes;Journal of Nutritional Science and Vitaminology;2024-08-31

2. CTNNB1 exon 3 mutations in metastatic solid pseudopapillary neoplasm of the pancreas;Journal of Surgical Oncology;2024-08-19

3. Plasma extracellular vesicle microRNAs reflecting the therapeutic effect of the CBP/β-catenin inhibitor PRI-724 in patients with liver cirrhosis;Scientific Reports;2024-03-15

4. Mechanism-based target therapy in primary biliary cholangitis: opportunities before liver cirrhosis?;Frontiers in Immunology;2023-05-30

5. Anti-inflammatory and antifibrotic effects of CBP/β-catenin inhibitor for hepatocytes: small molecular inhibitor, OP-724 possibly improves liver function;Medical Molecular Morphology;2023-01-16